Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In Italy, newly diagnosed Multiple Myeloma (MM) patients not eligible for autologous stem cell transplantation (ASCT) recently benefitted from a therapeutic advancement with the reimbursement of the combination daratumumab plus lenalidomide and dexamethasone (DRd) as frontline treatment. The introduction of this combination in first-line (1 L) is expected to generate an unmet medical need in second-line (2 L), since there are only three 2 L therapeutic options recommended by ESMO guidelines and reimbursed in Italy for lenalidomide-refractory patients post-DRd.
Materials And Methods: An epidemiological model was developed to estimate the number of Italian patients progressing to 2 L therapy after receiving DRd in 1 L over a 3-year time horizon (2025-2027) following a three-step procedure: (1) identification of the cohort of patients starting 1 L therapy with DRd in each quarterly cycle; (2) estimation of the number of patients experiencing disease progression or death in each cycle, through the long-term extrapolation of the progression-free survival (PFS) curve from the DRd clinical trial; (3) calculation of the number of patients eligible for 2 L therapy in each cycle.
Results: The cumulative number of ASCT-ineligible MM patients in 2 L after receiving DRd in 1 L in Italy amounts to 1743 between 2025 and 2027.
Conclusion: This study highlights the increasingly urgent unmet medical need developing in the 2 L setting following DRd in Italy, due to the large number of patients relapsing after 1 L therapy with DRd, for whom available treatment options are limited as they might not be eligible for DRd, thus intensifying their disease burden.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2025.07.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of UNOS: Trends in Heart Transplantation for Adults With Congenital Heart Disease in the United States Over 35 Years - A Comparison of Two Eras.
World J Pediatr Congenit Heart Surg
September 2025
Congenital Heart Center, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL, USA.
The purpose of this study is to identify 35-year trends in adult congenital heart disease (ACHD) heart transplant volume, transplant centers, patient characteristics, and longitudinal survival up to ten years. We performed a retrospective review of ACHD patients (≥18 years) who underwent heart transplantation (N = 2,297 transplants) between January 1, 1988, and December 31, 2022, using the United Network for Organ Sharing Database. Trends in transplant volume, transplant centers, patient characteristics, and longitudinal survival were analyzed.
View Article and Find Full Text PDFPrevention of Incisional Hernias With Prophylactic Synthetic Mesh Placement During Stoma Reversal: A Randomized Clinical Trial.
JAMA Surg
September 2025
Department of Surgery, Meander Medical Center, Amersfoort, the Netherlands.
Importance: Stoma reversal is associated with few complications. However, recent studies show that 1 in 3 patients develop an incisional hernia, for which half of the patients receive surgical correction.
Objective: To investigate whether prophylactic synthetic mesh placement in the retromuscular space during stoma reversal reduces the rate of stomal site incisional hernias.
Race, Ethnicity, Insurance Payer, and Pediatric Cardiac Arrest Survival.
JAMA Netw Open
September 2025
Division of Critical Care Medicine, Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Importance: Lower survival rates among Black adults relative to White adults after in-hospital cardiac arrest are well-described, but these findings have not been consistently replicated in pediatric studies.
Objective: To use a large, national, population-based inpatient database to evaluate the associations between in-hospital mortality in children receiving cardiopulmonary resuscitation (CPR) and patient race or ethnicity, patient insurance status, and the treating hospital's proportion of Black and publicly insured patients.
Design, Setting, And Participants: This retrospective population-based cohort study used the Healthcare Cost and Utilization Project Kids' Inpatient Database (1997-2019 triennial versions).
Evaluation of ambulatory use of daratumumab hyaluronidase injection.
J Oncol Pharm Pract
September 2025
Hematology/Oncology, Scripps Clinic, La Jolla, USA.
IntroductionDaratumumab is a therapeutic cornerstone of the management of multiple myeloma, exerting its anti-myeloma activity through targeting of the cell surface glycoprotein CD38 on plasma cells. While originally given intravenously, the subcutaneous formulation, daratumumab hyaluronidase injection (Dara SC), has been associated with non-inferior efficacy and lower infusion-related reaction rates (IRRs) in the treatment of multiple myeloma and light chain amyloidosis. A noted benefit of Dara SC is a short administration time; however, the optimal observation time post injection to ensure patient safety is unclear from the drug labeling.
View Article and Find Full Text PDFFrom neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.
Eur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.